China
Africa
Explore chapters and articles related to this topic
Composition of Proprietary Products Approved in the United States
Published in Sarfaraz K. Niazi, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition, 2019
LEVOTHROID® (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3′,5,5′-tetraiodothyronine sodium salt (levothyroxine [T4] sodium). Inactive ingredients: microcrystalline cellulose, calcium phosphate dibasic, povidone, and magnesium stearate. The following are the coloring additives per tablet strength: 25, FD&C Yellow No. 6 Aluminum Lake; 50, None; 75 FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake; 88, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake; 100, FD&C Yellow No. 6 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake; 112, D&C Red No. 27 Aluminum Lake, D&C Red No. 30 Aluminum Lake; 125, FD&C Blue No. 1 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake; 137, FD&C Blue No. 1 Aluminum Lake; 150, FD&C Blue No. 2 Aluminum Lake; 175, FD&C Blue No. 1 Aluminum Lake, D&C Red No. 30 Aluminum Lake, D&C Red No. 27 Aluminum Lake; 200, FD&C Red No. 40 Aluminum Lake; 300, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No.1 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake.
Iodine is needed to maintain health
Published in Tatsuo Kaiho, Iodine Made Simple, 2017
Idoxuridine is an antivirus ophthalmic solution and is generally used as a therapeutic drug for keratitis occurring resulting from inflammation due to viral infection. Levothyroxine is the oldest iodine-containing drug used as a thyroid hormone agent. There are two types of thyroid hormones, namely triiodothyronine (T3) and thyroxine (T4). T3 activity is said to be several times stronger than T4 (see Section 17) [44].
Physical activity, sports participation and exercise-related constraints in adult women with primary hypothyroidism treated with thyroid hormone replacement therapy
Published in Journal of Sports Sciences, 2021
Jeannette A.C. Lankhaar, Ellen Kemler, Hedwig Hofstetter, Dorine C.M. Collard, Pierre M.J. Zelissen, Janine H. Stubbe, Frank J.G. Backx
Primary hypothyroidism is the second most common endocrine disease worldwide after diabetes mellitus and is caused by thyroid hormone deficiency. Hypothyroidism can be categorised based on its time of onset (congenital or acquired) and its severity, as in overt (clinical), subclinical, and mild diseases (Biondi & Wartofsky, 2014). The prevalence of overt hypothyroidism in the general population varies between 0.3% and 3.7% in the USA and between 0.2% and 5.3% in Europe (Åsvold et al., 2013; Aoki et al., 2007; Canaris et al., 2000; Garmendia Madariaga et al., 2014; Hollowell et al., 2002), depending on the definition used (Chaker et al., 2017). Hypothyroidism affects women 10 times more frequently than men, and its rate increases with age (Vanderpump, 2011). Hashimoto’s thyroiditis, which is also referred to as autoimmune thyroiditis (AIT), is characterised by the presence of thyroid peroxidase antibody (TPO-Ab) in serum and is the most common cause of hypothyroidism (Caturegli et al., 2014; Chaker et al., 2017; Vanderpump, 2011). The standard treatment of hypothyroidism is thyroid hormone replacement therapy (THR) with levothyroxine (Chaker et al., 2017), which is one of the main prescribed drugs worldwide (Korevaar et al., 2018).